18 results about "Staphylococcus epidermidis" patented technology

The present invention relates to the use of a combination of a saccharide and glycerol for skin protection against undesirable bacteria. The present invention is particularly useful in the formulation of compositions that act as prebiotics for commensal skin bacteria such as S. epidermidis to produce metabolites such as lactic acid, which, through the present invention, has been shown to inhibit the growth of undesirable bacteria such as E. coli and S. aureus, among others. The present invention is especially useful because it provides both short-term (i.e., rapid) and long-term (or sustained) protection.

The present invention relates to the field of biological fermentation application technology, and in particular, to use of a milk peptide fermentation product in regulating skin microecological balance. The milk peptide fermentation product selectively regulates the growth of Staphylococcus epidermidis and inhibits the growth of Staphylococcus aureus and Escherichia coli. It was discovered for the first time that the milk peptide fermentation product has a selective bacteriostatic effect on skin microorganisms. The experimental results show that the milk peptide fermentation product has an inhibitory effect on Escherichia coli and Staphylococcus aureus, but has no effect on the normal growth of Staphylococcus epidermidis. This characteristic is obviously different from common broad-spectrum chemical bacteriostatic agents, and the use of the milk peptide fermentation product is more conducive to maintaining the balance of skin microbiota.

This invention belongs to the field of peptide drugs, specifically relating to an anti-drug-resistant bacterial peptide and its application in pharmaceutical manufacturing. Using Rink amide MBHA amino resin as a solid-phase support, the amino acid sequence of the template peptide raniseptin PL:Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 was modified, with amino acid residues 9I and 16F replaced by R8 and S5, respectively, to obtain the target stapling peptide PL-11. Compared to the template peptide PL-0, the stapling peptide PL-11 significantly enhances the antibacterial activity against Staphylococcus aureus, Enterococcus faecalis, and Staphylococcus epidermidis.

This invention belongs to the field of peptide drugs, specifically relating to an anti-drug-resistant bacterial peptide and its application in pharmaceutical manufacturing. Using Rink amide MBHA amino resin as a solid-phase support, the amino acid sequence of the template peptide raniseptin PL:Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 was modified, with amino acid residues 6V and 13V replaced by R8 and S5, respectively, to obtain the target stapling peptide PL-10. Compared to the template peptide PL-0, the stapling peptide PL-10 significantly enhances the antibacterial activity against Staphylococcus aureus, Enterococcus faecalis, and Staphylococcus epidermidis.

The application discloses a natural product 3-methylcarbazole derivative with a general formula B and a preparation method and application thereof in the technical field of organic chemistry. S. aureus S. epidermidis The derivative has good antibacterial activity, can significantly inhibit Staphylococcus aureus, Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus (MRSA), and can be used for preparing a drug for treating related bacterial infections.​

This invention belongs to the field of peptide drugs, specifically relating to an antibacterial peptide and its application in pharmaceutical manufacturing. Using Rink amide MBHA amino resin as a solid-phase support, the amino acid sequence of the template peptide raniseptin PL:Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 was modified, with amino acid residues 13V and 20V replaced by R8 and S5, respectively, to obtain the target stapling peptide PL-13. Compared to the template peptide PL-0, the stapling peptide PL-13 significantly enhances the antibacterial activity against Staphylococcus aureus, Enterococcus faecalis, and Staphylococcus epidermidis.

The application belongs to the field of polypeptide drugs, and particularly relates to an antibacterial polypeptide and application thereof in pharmacy. The application takes Rink amide MBHA amino resin as a solid phase carrier, and modifies and transforms according to a template polypeptide raniseptin PL:Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 amino acid sequence, wherein amino acid residues 19G and 26N are replaced by R8 and S5, to obtain a target stapled peptide PL-16. The stapled peptide PL-16 can significantly improve the antibacterial activity on Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis and Staphylococcus epidermidis relative to the template polypeptide PL-0.

The application discloses a fusion membrane of Staphylococcus epidermidis vesicles and curcumin-derived exosome-like vesicles and a preparation method and application thereof. The application fuses Staphylococcus epidermidis vesicles and curcumin-derived exosome-like vesicles to obtain HMVs, and verifies the antibacterial effect of the HMVs through in-vitro experiments, and then the HMVs are loaded in hyaluronic acid microneedles. The HMVs MNs nano system can be locally administered by pressing on acne lesions, and the in-vivo experiments on Balb / c mice prove that the system has relatively remarkable antibacterial and anti-inflammatory effects. Therefore, the HMVs MNs have relatively good application potential in treating acne.

This invention discloses the application of an artemisia annua compound as the sole active ingredient in the preparation of topical formulations for the prevention or improvement of blackheads and acne. Based on 100% of the total mass of the topical formulation, the artemisia annua compound accounts for 0.1% to 0.22%, and is composed of the following raw materials in parts by mass: camphene 4 to 10 parts, artemisinin 1 part. This invention also discloses a topical formulation for the prevention or improvement of blackheads and acne, the sole active ingredient of which is an artemisia annua compound. Based on 100% of the total mass of the topical formulation, the artemisia annua compound accounts for 0.1% to 0.22%, and is composed of the following raw materials in parts by mass: camphene 4 to 10 parts, artemisinin 1 part. The artemisia annua compound of this invention can significantly reduce the formation of squalene peroxide in a UVA-induced squalene photo-oxidation model, and shows stronger inhibition against Malassezia and less impact on Staphylococcus epidermidis in a Malassezia vs. symbiotic bacteria comparison model.

This invention discloses the application of dermal ethylsin in the preparation of antibacterial and repairing cosmetics or pharmaceuticals, and compositions containing it. Dermal ethylsin can inhibit Propionibacterium acnes, Staphylococcus aureus, and / or Staphylococcus epidermidis, and can promote keratinocyte migration and / or upregulate the expression of repair-related genes. Cytotoxicity tests show that dermal ethylsin has good safety. Human efficacy evaluation shows that serums containing dermal ethylsin can significantly reduce inflammatory papules, improve skin redness, and improve barrier function. Therefore, dermal ethylsin can be used as a dual-action antibacterial and repairing active agent in cosmetics or pharmaceuticals for acne skin care, sensitive skin repair, and / or post-medical aesthetic repair. Dermal ethylsin is derived from *Gnaphalium affine*, has good safety, and is non-irritating to the skin.

The present application relates to a kind of staphylococcus epidermidis outer vesicle and its preparation method and application, the preparation method of the staphylococcus epidermidis outer vesicle includes the following steps: S1, staphylococcus epidermidis CCSMS0776 is inoculated in TSB culture medium and is cultivated, obtains staphylococcus epidermidis CCSMS0776 culture;S2, staphylococcus epidermidis CCSMS0776 culture obtained in S1 step is centrifuged, and supernatant is collected to ultrafiltration, obtains concentrated solution;S3, the concentrated solution obtained in S2 step is centrifuged, and supernatant is filtered, and then the filtrate is carried out ultra-high speed centrifugation, and the collection precipitate is resuspended in PBS, obtains staphylococcus epidermidis outer vesicle.Compared with prior art, the bacterial outer vesicle prepared in the present application shows good anti-inflammatory and skin barrier repair effect, and has wide application prospect in the protection of light damage and the treatment of inflammatory skin diseases and soothing skin care product.

The application belongs to the field of polypeptide drugs, and particularly relates to an antibacterial polypeptide and application thereof. The Rink amide MBHA amino resin is used as a solid phase carrier, and a template polypeptide raniseptin PL: Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 amino acid sequence is modified and reformed. On the basis of reserving key amino acid residues, S5 and R8 are respectively used to replace original amino acids at i, i+4 and i, i+7 amino acid positions, so that a target stapled peptide is obtained. The stapled peptide can significantly improve the antibacterial activity on Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis and Staphylococcus epidermidis relative to the template polypeptide PL-0.

The present application belongs to the technical field of plant extraction, and discloses a wheat germ extract and use. The wheat germ extract contains luteoloside, quercitrin and rutin, and the total content of the luteoloside, quercitrin and rutin is greater than or equal to 2000 ppm. The present application discloses a wheat germ extract, wherein the total content of luteoloside, quercitrin and rutin is greater than or equal to 2000 ppm, has an excellent effect of improving staphylococcus epidermidis lipase activity, and through improving staphylococcus epidermidis lipase activity, the effect of promoting skin regulation of lipid component structure is obtained.

The application discloses a private part care spray capable of balancing private part microecology, removing peculiar smell, killing bacteria and resisting viruses, and belongs to the technical field of private part care and disinfection materials. The private part care spray is prepared by compounding 3.8-6.5 parts of a modified edible bactericide, 3.2-5.5 parts of food-grade lactic acid, 2.2-3.0 parts of modified food-grade gentian root extract and the rest food-grade deionized water. The activity and stability of raw materials are improved through the processes of β-cyclodextrin inclusion modification of the bactericide and compounding of the modified product with the modified food-grade gentian root extract. The product has a killing rate of 99.9% on Neisseria gonorrhoeae, Gardnerella vaginalis, Bacteroides, Streptococcus pyogenes, Candida albicans, Staphylococcus epidermidis, Escherichia coli and Pseudomonas aeruginosa, an inactivation rate of 99.99% on herpes simplex virus SHV-2 and HPV16 virus, an ammonia removal rate of 95%, a peculiar smell inhibition duration of 48 h and a mucous membrane irritation level of 0, and the preparation process is simple and suitable for industrial production.

The present application relates to the field of ophthalmic drugs, and particularly relates to an ophthalmic composition, a preparation method and application thereof, the ophthalmic composition comprising a compound as shown in formula I, an osmotic pressure regulator, a pH regulator and water for injection; the pH value of the ophthalmic composition is 4.0-6.0; the concentration of the compound as shown in formula I is 0.1-3.0% w / v, and the concentration of the osmotic pressure regulator is 0.3-10.0% w / v; the antibacterial activity against Streptococcus pneumoniae, Staphylococcus aureus and Staphylococcus epidermidis is 2-8 times that of levofloxacin and moxifloxacin hydrochloride; the antibacterial activity against Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli and Pseudomonas aeruginosa is also strong, and is equivalent to that of levofloxacin and moxifloxacin hydrochloride; the irritation is small, the light stability and high-temperature stability are good, the quality and drug safety are guaranteed, and the application value is good.

The present application aims to provide a eucheuma extract, a preparation method and application thereof, and the preparation method comprises the following steps: cutting eucheuma whole grass, using distilled water and 75% ethanol as extraction solvents respectively, hot reflux extraction twice, combining the filtrates, concentrating under reduced pressure, and evaporating the solvent to dryness to prepare a dry paste, and obtaining eucheuma water extract and eucheuma alcohol extract respectively. The eucheuma water extract and alcohol extract provided by the present application have significant inhibitory effects on staphylococcus aureus, escherichia coli, staphylococcus epidermidis, methicillin-resistant staphylococcus epidermidis, sarcina, bacillus, pseudomonas aeruginosa, enterococcus faecium, micrococcus luteus, acinetobacter baumannii, streptococcus pneumoniae and klebsiella pneumoniae, and have great development potential in the future research on bacteriostatic drugs, bacteriostatic cleaning products and other bacteriostatic products.

This invention relates to a bacterial strain that improves the physical structure of red mud and its application. The strain BRT1 is classified as Staphylococcus epidermidis. Staphylococcus epidermidis The accession number is GDMCC No. 66375, the accession date is May 22, 2025, and the depositary institution is Guangdong Microbial Culture Collection Center. This invention utilizes the BRT1 strain, which efficiently improves the physical structure of red mud, solving the technical problem of poor red mud structure. The BRT1 strain secretes extracellular polymeric substances (EPS) as a bio-cementitious agent, effectively promoting the aggregation of red mud particles and forming stable aggregate structures.

To provide recombinant Staphylococcus bacteria (e.g., S. epidermidis) that are dependent on D-alanine for growth. [Solution] In one aspect, the Disclosure features recombinant Staphylococcus bacteria comprising two inactivated alanine racemase genes (Δalr1Δalr2); and an inactivated D-alanine aminotransferase (dat) gene. In another aspect, the Disclosure features a method for producing recombinant Staphylococcus bacteria. In another aspect, the Disclosure provides a method for treating or preventing a rash in a subject, the method comprising the step of administering to the subject an amount effective to treat or prevent a rash in the subject, which is one of the aspects or embodiments described herein.